LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune
Expansion of Biopharma precision solutions in the field of Immuno-Oncology LAUSANNE, SWITZERLAND - November 15, 2022 – Novigenix SA, a leading data-driven precision medicine biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced successful first closing of its $20 million Series B financing round with participation from existing and new investors. Novigenix‘s
New LITOseek biomarkers presented at ESMO have identified upregulation of ribosomal biogenesis and TCR signaling with downregulation of interferon gene clusters in responsive patients LAUSANNE, SWITZERLAND - September 9th, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions today announced discovery of new Immuno-Transcriptomic signatures for prediction of
New precision solutions may be accessible on Philips IntelliSpace Precision Medicine Platform LAUSANNE, SWITZERLAND - March 8, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced a Technology License Agreement with Royal Philips (‘Philips’) for development of new tissue biopsy Prostate cancer (PCa) Immuno-Transcriptomic tests to
LAUSANNE, SWITZERLAND – February 1st, 2022 – Novigenix Co-founder and CTO Dr Sahar Hosseinian shares her successful path to founding Novigenix and entrepreneurship in an interview by Lausanne’s Life Science Hub Biopôle. “I met two biologists who were hugely inspiring and had amazing data that leveraged the host response in cancer patients to save
Novigenix expands Advisory Board with influential scientific and commercial opinion leaders LAUSANNE, SWITZERLAND - October 26th, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions is thrilled to announce the nomination of three leading figures to the Advisory Board. "We are pleased and honored to welcome Professor
Publication in Cancers Journal Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 LAUSANNE, SWITZERLAND - September 23rd, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced release of the article: “Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell
Company expands precision medicine solutions for drug development and clinical utility programs. LAUSANNE, SWITZERLAND - August 31, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced election of Dr. Miro Venturi to its Board of Directors. Dr. Venturi is currently Group CEO of Sintetica SA,
Schweizer Firma erhält Felix Burda Award für Bluttest, der Darmkrebs erkennt Ein Biotech-Unternehmen hat einen Bluttest entwickelt, der Darmkrebs und dessen Vorstufen mit hoher Wahrscheinlichkeit erkennt. Die Basis dafür bilden Biomarker im Blut. Für diesen Fortschritt in der Darmkrebs-Vorsorge erhalten sie den Felix Burda Award 2021. Im zweiten Teil der virtuellen Preisverleihung geht der
Kategorie „Innovation in der Immuno-Transkriptomik zur Früherkennung von Darmkrebs" Auszeichnung würdigt herausragende Innovation und Wirkung bei der Früherkennung von Krebs LAUSANNE, Schweiz, 22. Juli 2021 /PRNewswire/ -- Novigenix SA, ein führendes Schweizer Biotech-Unternehmen, das immuno-transkriptomische Präzisions-Onkologielösungen entwickelt und vermarktet, gab heute bekannt, dass es mit dem Felix Burda Award 2021 in der Kategorie Medizin